Rezolute (RZLT) Intangibles (2013 - 2020)
Rezolute recorded quarterly Intangibles of $24000.0 in Q1 2020, down 7.69% quarter-over-quarter from $26000.0 in Q4 2019, and down 23.96% year-over-year from $31561.0 in Q2 2019.
Rezolute's Intangibles history runs 8 years deep, the most recent figure standing at $24000.0 for Q1 2020.
- In Q1 2020, Intangibles fell 23.96% year-over-year to $24000.0; the TTM figure through Mar 2020 stood at $24000.0 (down 23.96% YoY), while the FY2019 annual figure was $29000.0, down 21.62% from the prior year.
- Intangibles came in at $24000.0 for Q1 2020 at Rezolute, down from $26000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $53437.0 in Q1 2016 to a low of $24000.0 in Q1 2020.
- A 5-year average of $38791.6 and a median of $38853.0 in 2018 frame the typical range for Intangibles.
- Across the five-year window, Intangibles decreased 12.01% in 2016 and retreated 23.96% in 2020, its largest moves.
- Rezolute's Intangibles stood at $47968.0 in 2016, then fell by 15.2% to $40676.0 in 2017, then fell by 17.93% to $33384.0 in 2018, then decreased by 22.12% to $26000.0 in 2019, then decreased by 7.69% to $24000.0 in 2020.
- According to Business Quant data, Intangibles over the past three periods registered $24000.0, $26000.0, and $28000.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.41 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 11,640.44 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 418.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.29 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 24,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Sep 30, 2019 | 28,000.00 |
| Jun 30, 2019 | 29,000.00 |
| Mar 31, 2019 | 31,561.00 |
| Dec 31, 2018 | 33,384.00 |
| Sep 30, 2018 | 35,207.00 |
| Jun 30, 2018 | 37,000.00 |
| Mar 31, 2018 | 38,853.00 |
| Dec 31, 2017 | 40,676.00 |
| Sep 30, 2017 | 42,499.00 |
| Jun 30, 2017 | 44,322.00 |
| Mar 31, 2017 | 46,145.00 |
| Dec 31, 2016 | 47,968.00 |
| Sep 30, 2016 | 49,791.00 |
| Jun 30, 2016 | 51,614.00 |
| Mar 31, 2016 | 53,437.00 |
| Dec 31, 2015 | 55,260.00 |
| Sep 30, 2015 | 57,083.00 |
| Jun 30, 2015 | 58,906.00 |
| Mar 31, 2015 | 60,729.00 |
| Dec 31, 2014 | 62,552.00 |
| Sep 30, 2014 | 8,866.00 |
| Jun 30, 2014 | 9,161.00 |
| Mar 31, 2014 | 10,047.00 |
| Dec 31, 2013 | 10,933.00 |
| Sep 30, 2013 | 11,819.00 |
| Jun 30, 2013 | 12,705.00 |
| Mar 31, 2013 | 13,000.00 |